Skip to content
Clinical Trials – home
Therapeutic area

Eye disorders – page 13

  • 369 clinical trials
  • 123 recruiting
  • 134 conditions
  • 27 countries

Conditions in this area

134 conditions with trials, the busiest first

Clinical trials in Eye disorders

369 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

369 clinical trials

Giant cell arteritis+1

Not yet recruiting

Diagnostic Accuracy of 68Ga‑FAPI‑46 PET/CT in Patients with Suspected Giant Cell Arteritis and Polymyalgia Rheumatica

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Universitair Medisch Centrum Groningen

Stargardt's disease

Not yet recruiting

A study to evaluate the safety and effectiveness of AAVB-039 in patients with Stargardt disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Sponsor:Aavantgarde Bio S.r.l.

A study to evaluate the safety and effectiveness of ADX-038 in adults with geographic atrophy caused by age-related macular degeneration.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ADX-038
  • Sponsor:Adarx Pharmaceuticals Inc.

Axial spondyloarthritis+1

Not yet recruiting

Study to evaluate the effect of upadacitinib on the frequency of eye inflammation in patients with axial spondyloarthritis.

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:Care Arthritis Ltd.

Sjogren's syndrome

Not yet recruiting

A study to evaluate the effect of obinutuzumab on removing specific immune cells in the tissues of patients with Sjögren's syndrome.

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Stichting Radboud University Medical Center

Hereditary optic atrophy

Not yet recruiting

A study to evaluate the effectiveness of nicotinamide in patients with Leber's hereditary optic neuropathy who have experienced vision loss within the last 18 months

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nicotinamide
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Endocrine ophthalmopathy

Not yet recruiting

A study testing teprotumumab compared to placebo in adult patients with moderate-to-severe active thyroid eye disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Teprotumumab
  • Sponsor:Horizon Therapeutics USA Inc.

Uveal melanoma

Not yet recruiting

A study comparing RP2 with nivolumab versus ipilimumab with nivolumab in adults with metastatic uveal melanoma not previously treated with immune checkpoint inhibitors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Replimune Group Inc.

Endocrine ophthalmopathy+1

Not yet recruiting

A study to test if atorvastatin can prevent eye disease in patients newly diagnosed with Graves' disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Region Skane

Normal tension glaucoma

Not yet recruiting

A Study of Isosorbide Mononitrate for Patients with Normal Tension Glaucoma to Improve Blood Flow to the Optic Nerve

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Sponsor:University Of Helsinki

Conjunctivitis allergic+1

Not yet recruiting

A Study Comparing Tacrolimus and Ciclosporin Eye Drops for Children and Adults with Moderate to Severe Vernal Keratoconjunctivitis

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Ciclosporin
  • Sponsor:Laboratoires Thea

Conjunctivitis allergic

Not yet recruiting

Testing Intralymphatic Allergen Immunotherapy for Teenagers and Adults with Grass Pollen Allergy Causing Hay Fever or Asthma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:University Of Foggia

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.